Project Grant R61DA064790
- Federal Grant Award Summary The University of Massachusetts Medical School received a $2.19 million Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the five-year "Supporting Treatment Access and Recovery in Re-entry (STAR-R)" randomized controlled trial. Beginning September 1, 2025, and concluding May 31, 2030, this research initiative will evaluate the effectiveness of the Maintaining...
- Federal Grant Award Summary The University of Kentucky Research Foundation was awarded $4.34 million under the National Institute on Drug Abuse's Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Kentucky Women's Justice Community Overdose Innovation Network Phase II (WJCOIN-II) project. The award, effective September 1, 2025 through May 31, 2030, supports a multi-site, randomized controlled trial designed to reduce overdose risk among women transitioning from jail to rural...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $647,142 Project Grant to The University of Kentucky Research Foundation under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder (OUD). The award, effective February 15, 2026 through November 30, 2030, funds two randomized, double-blind, placebo-controlled inpatient...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Research Triangle Institute (RTI International) a $1,985,550 Project Grant on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a hybrid Type I randomized controlled trial assessing the effectiveness of a peer-led court navigation intervention for facilitating linkage to substance use disorder (SUD) treatment. The award extends through May 31, 2030, and will test...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Kentucky Research Foundation a $1.85 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 1, 2025, through February 29, 2028. This award supports a human laboratory study investigating immune inflammation as a treatment target for cocaine use disorder through administration of pentoxifylline, a phosphodiesterase inhibitor with anti-inflammatory...
- Federal Project Grant Award Summary The University of Kentucky Research Foundation received a $1.46M Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized, controlled clinical trial evaluating non-abstinence treatment outcomes for individuals with methamphetamine use disorder (MUD). Awarded on September 30, 2025, with a completion date of May 31, 2030, the research will deliver evidence on how reduced...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $1.255 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct human laboratory research translating preclinical findings on troriluzole as a pharmacotherapy for methamphetamine use disorder (MUD). The award, obligated on April 15, 2025, with a completion date of February 28, 2029, supports a clinical study evaluating...
- Federal Grant Award Summary The University of Rochester received a $433,029 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot a novel couples-based treatment intervention for dual substance use disorder (DUD) in heterosexual couples. The award, effective March 15, 2026 through February 28, 2028, addresses a critical gap in addiction treatment by creating a specialized intervention tailored to...
- Federal Grant Award Summary Partnership To End Addiction received a $453,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 15, 2026 through February 29, 2028. The award funds development and evaluation of HALO (Helping Affected Loved Ones), an artificial intelligence-powered chatbot designed to deliver evidence-based, real-time support to concerned significant others (CSOs)—primarily...
- Federal Grant Award Summary The University of Connecticut Health Center received a $191,700 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) on February 15, 2026, with completion scheduled for January 31, 2028. This K99/R00 award supports research to identify and validate mechanisms of action (MOA) underlying peer recovery support (PRS) services for individuals with opioid use disorder (OUD). The project aims to...
The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $422,921 Project Grant on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test the STAR (Support Towards Addiction Recovery) intervention. This dyadic intervention is designed to improve recovery outcomes for individuals with substance use disorder (SUD) who have involvement in the criminal legal system (CLS) by simultaneously supporting both the recovering individual and their identified loved one. The project will be conducted in Lexington, Kentucky, with a completion date of February 28, 2027. The grant funds a two-phase project beginning with an R61 adaptation and feasibility testing phase, during which the research team will strategically adapt recovery coaching services using the ADAPT-ITT framework to serve recovering individuals with CLS involvement and their supportive loved ones through delivery in recovery community centers. The intervention will include one-on-one sessions with both a recovery coach and a loved one coach, along with structured joint dyad sessions. This is followed by an R33 effectiveness and implementation phase employing a hybrid Type 1 effectiveness-implementation design to evaluate the adapted STAR intervention's impact on building recovery capital and sustaining recovery efforts for both the recovering person and their loved ones.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $422.9k | 2/24/26 |